{"id":2834,"date":"2017-02-03T20:17:25","date_gmt":"2017-02-03T20:17:25","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=20384"},"modified":"2017-02-03T20:17:25","modified_gmt":"2017-02-03T20:17:25","slug":"axim-biotechnologies-canchew-gum-clinical-trials-featured-cbs-evening-news-new-york","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/02\/03\/axim-biotechnologies-canchew-gum-clinical-trials-featured-cbs-evening-news-new-york\/","title":{"rendered":"AXIM\u00ae Biotechnologies and CanChew\u00ae Plus Gum Clinical Trials Featured on CBS Evening News New York"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text]CanChew\u00ae Plus and AXIM\u00ae Biotechnologies were part of a news segment this week on CBS New York regarding the company\u2019s <\/span>ongoing clinical trials<\/span><\/a> for the use of its patented CanChew\u00ae Plus CBD gum for the treatment of irritable bowel syndrome or IBS. <\/span><\/p>\n \u201cWe are pleased to have reached another milestone in the development of AXIM products to treat challenging health conditions,\u201d said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM\u00ae Biotech on starting the clinical trial.<\/span><\/p>\n Following successful PK\/PD trials to test possible effective dosing, AXIM\u00ae Biotechnologies will be testing a 50 mg dose of CBD per piece of chewing gum in the Phase II clinical trial.\u00a0<\/span><\/p>\n AXIM\u00ae\u2019s clinical trial for IBS is being completed in the Netherlands. The terms of the clinical trial allow patients up to 6 doses of 50 mg a day to control their symptoms of IBS, such as stomach cramps, bloating, and pain. The clinical trial will include 40 patients, aged from 18-65, who have been diagnosed with IBS according to <\/span>ROME III criteria<\/span><\/a>, which includes abdominal pain that occurs at least three times a month for three months and a change in stool frequency or consistency.<\/span><\/p>\n If the trials on AXIM\u00ae\u2019s Canchew\u00ae Plus gum are successful, the company will test it against more severe forms of IBD in the future. The company received the necessary funding last November to pursue a number of clinical trials, including the current IBS trial. The company also released their clinical trial schedule relaying the progress the company is making towards creating prescription cannabis products. <\/span><\/p>\n AXIM\u00ae Biotechnologies is an innovative biotechnology company focusing on the research, development, and production of cannabinoid-based pharmaceuticals and nutraceutical supplements.<\/span><\/p>\n View the full news segment <\/span>HERE<\/span><\/a>.<\/span><\/p>\n For more information on AXIM Biotechnologies and their products, visit\u00a0<\/span>http:\/\/aximbiotech.com\/<\/span><\/a> or follow <\/span>our news feed<\/span><\/a>.<\/span>[\/vc_column_text][\/vc_column][\/vc_row] \t<\/p>\n","protected":false},"excerpt":{"rendered":" [vc_row][vc_column][vc_column_text]CanChew\u00ae Plus and AXIM\u00ae Biotechnologies were part of a news segment this week on CBS New York regarding the company\u2019s ongoing clinical trials for the use of its patented CanChew\u00ae Plus CBD gum for the treatment of irritable bowel syndrome or IBS. \u201cWe are pleased to have reached another milestone in the development of AXIM […]<\/p>\n","protected":false},"author":1,"featured_media":208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[160,3,162,9],"tags":[183],"class_list":["post-2834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-axim-biotechnologies","category-company-news","category-media-coverage","category-scientific-research","tag-axim-biotechnologies"],"yoast_head":"\n